600-22-6
Chemical Structure
Methyl pyruvate
- CAS No.: 600-22-6
- Formula:C4H6O3
- Molecular Weight:102.09
IUPAC Name: methyl 2-oxopropanoate
InChIKey: CWKLZLBVOJRSOM-UHFFFAOYSA-N
SMILES: O=C(OC)C(=O)C
Biological Activity: Methyl pyruvate is a p53/p21 axis inhibitor, intrinsic apoptosis inhibitor, cytotoxic agent, ATP production enhancer, proteasome function restorer, TDP-43 localization normalizer, ATP-sensitive potassium (K+ATP) channel inhibitor, depolarizer, and insulin secretagogue[1][3][4].Methyl pyruvate turns off apoptotic pathways, induces cancer cell death, acts as a substrate for dimeric dihydrodiol dehydrogenase, enhances TCA cycle activity, rescues proteasome impairment and TDP-43 mislocalization, inhibits K+ATP channels independent of ATP, depolarizes pancreatic β-cell membranes, modulates insulin secretion, and enters pancreatic β-cell mitochondria via a specific transporter[1][2][3][4].Methyl pyruvate can be used for the research of lung adenocarcinoma, ovarian clear cell adenocarcinoma, breast adenocarcinoma, amyotrophic lateral sclerosis, and type II diabetes[1][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Methyl pyruvate | 99.81% | Methyl pyruvate is a p53/p21 axis inhibitor, intrinsic apoptosis inhibitor, cytotoxic agent, ATP production enhancer, proteasome function restorer, TDP-43 localization normalizer, ATP-sensitive potassium (K+ATP) channel inhibitor, depolarizer, and insulin secretagogue.Methyl pyruvate turns off apoptotic pathways, induces cancer cell death, acts as a substrate for dimeric dihydrodiol dehydrogenase, enhances TCA cycle activity, rescues proteasome impairment and TDP-43 mislocalization, inhibits K+ATP channels independent of ATP, depolarizes pancreatic β-cell membranes, modulates insulin secretion, and enters pancreatic β-cell mitochondria via a specific transporter.Methyl pyruvate can be used for the research of lung adenocarcinoma, ovarian clear cell adenocarcinoma, breast adenocarcinoma, amyotrophic lateral sclerosis, and type II diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Monchusi B, et al. Methyl pyruvate protects a normal lung fibroblast cell line from irinotecan-induced cell death: Potential use as adjunctive to chemotherapy. PloS one. 2017;12(8):e0182789. [Content Brief]
- [2]. Sato K, et al. Purification and characterization of dimeric dihydrodiol dehydrogenase from dog liver. Journal of biochemistry. 1994 Sep;116(3):711-7. [Content Brief]
- [3]. Tagashira H, et al. Methyl pyruvate rescues mitochondrial damage caused by SIGMAR1 mutation related to amyotrophic lateral sclerosis. Biochimica et biophysica acta. 2014 Dec;1840(12):3320-34. [Content Brief]
- [4]. Lembert N, et al. Methyl pyruvate initiates membrane depolarization and insulin release by metabolic factors other than ATP. The Biochemical journal. 2001 Mar 01;354(Pt 2):345-50. [Content Brief]
